NasdaqGS:RAREBiotechs
Ultragenyx Pharmaceutical (RARE) Heavy Q1 EPS Loss Tests Bulls Profitability Timeline Narrative
Ultragenyx Pharmaceutical (RARE) opened Q1 2026 with revenue of US$136 million and basic EPS of US$1.84 loss, while trailing twelve month figures show revenue of US$670 million and basic EPS of US$6.11 loss. Over recent quarters, revenue has moved between US$139.3 million in Q1 2025 and US$207.3 million in Q4 2025, as basic EPS losses ranged from US$1.17 to US$1.81 per quarter. This gives investors a clear view of how top line growth is running ahead of earnings. For anyone watching margins...